ll be well positioned to acquire/license DDF-developed drugs/companies in due course • DDF has raised -£100M to date from strategic investors, and Woodford Investment Management (to close in April). DDF is now seeking an additional £130M to reach its target I ttheimer's Research Department UK of Health Biogen A95tS2c.